Alternative mechanisms of action have since gained traction in MASH treatment. Madrigal Pharmaceuticals’s Rezdiffra (resmetirom), a small molecule THRB agonist, was the first drug approved by the FDA ...

Eli Lilly has begun the week with a bang ... them on radiopharmaceuticals and metabolic-associated steatohepatitis (MASH), respectively. The deal with OliX gives Lilly global rights to OLX75016 ...

Eli Lilly is paying up to $630m for a Phase I metabolic-associated steatohepatitis (MASH) candidate from South Korea-based biotech OliX Pharmaceuticals, diversifying its pipeline for the disease ...

On Monday, Eli Lilly And Co (NYSE:LLY) inked two strategic collaborations to expand radiopharmaceuticals and metabolic-associated steatohepatitis (MASH), respectively. AdvanCell announced that it ...

SEONGNAM, South Korea--(BUSINESS WIRE)--OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced a global licensing agreement with Eli Lilly and ...

Three months ago, in its third-quarter report, Madrigal pointed out that it achieved a key goal early by gaining 80% coverage ...

Eli Lilly (NYSE: LLY) stock defied today's market downturn, rising 2.6% through 11:15 a.m. ET on the back of two positive press releases. In one, Lilly announced plans to acquire the farnesoid X ...

Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market ...

The deal with Lilly is a crucial boost for Organovo, which ended last year with just $1.2 million in cash and nearly $350 million in debt. Organovo FXR is a clinical drug program focused on farnesoid ...

OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced a global licensing agreement with Eli Lilly and ... steatohepatitis (MASH) and other ...